A citation-based method for searching scientific literature

José Baselga, Javier Cortés, Sung-Bae Kim, Seock-Ah Im, Roberto Hegg, Young-Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pienkowski, Adam Knott, Emma Clark, Mark C Benyunes, Graham Ross, Sandra M Swain. N Engl J Med 2012
Times Cited: 1520







List of co-cited articles
635 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino,[...]. N Engl J Med 2012
43

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
34

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Sandra M Swain, José Baselga, Sung-Bae Kim, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiss, Sarah Heeson,[...]. N Engl J Med 2015
33

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, Deborah Lindquist, Stephen Chan, C Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman,[...]. N Engl J Med 2006
28

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani,[...]. N Engl J Med 2020
365
27

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A Hurvitz, Nancy U Lin, Virginia Borges, Vandana Abramson, Carey Anders,[...]. N Engl J Med 2020
290
26

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark,[...]. N Engl J Med 2017
566
23

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
22

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Sandra M Swain, David Miles, Sung-Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, Andreas Schneeweiss, Sherene Loi, Estefanía Monturus,[...]. Lancet Oncol 2020
112
20

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im,[...]. Lancet Oncol 2012
18

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Véronique Diéras, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E Krop, Kim Blackwell, Silke Hoersch, Jin Xu,[...]. Lancet Oncol 2017
224
17

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Edith A Perez, Carlos Barrios, Wolfgang Eiermann, Masakazu Toi, Young-Hyuck Im, Pierfranco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier Pivot, Howard Burris,[...]. J Clin Oncol 2017
189
16

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Sandra M Swain, Sung-Bae Kim, Javier Cortés, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiss, Adam Knott,[...]. Lancet Oncol 2013
600
16

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Ian E Krop, Sung-Bae Kim, Antonio González-Martín, Patricia M LoRusso, Jean-Marc Ferrero, Melanie Smitt, Ron Yu, Abraham C F Leung, Hans Wildiers. Lancet Oncol 2014
380
14

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Ian E Krop, Sung-Bae Kim, Antonio Gonzalez Martin, Patricia M LoRusso, Jean-Marc Ferrero, Tanja Badovinac-Crnjevic, Silke Hoersch, Melanie Smitt, Hans Wildiers. Lancet Oncol 2017
199
12

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann. Cancer Res 2009
384
11

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
11


Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, Lisa M Crocker, Kathryn L Parsons, Elaine Mai, Walter A Blättler, John M Lambert, Ravi V J Chari, Robert J Lutz,[...]. Cancer Res 2008
983
10

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Cristina Saura, Mafalda Oliveira, Yin-Hsun Feng, Ming-Shen Dai, Shang-Wen Chen, Sara A Hurvitz, Sung-Bae Kim, Beverly Moy, Suzette Delaloge, William Gradishar,[...]. J Clin Oncol 2020
95
10

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Hope S Rugo, Hiroji Iwata, Pierfranco Conte, Ingrid A Mayer, Bella Kaufman,[...]. N Engl J Med 2019
670
10

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch,[...]. N Engl J Med 2005
10

Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, Miguel Martin, Michael Press, John Mackey, John Glaspy, Arlene Chan, Marek Pawlicki,[...]. N Engl J Med 2011
10

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
625
9

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, John Bryant, Vera J Suman, Charles E Geyer, Nancy E Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A Kaufman,[...]. N Engl J Med 2005
9

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Starosławska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini,[...]. Lancet Oncol 2016
317
9

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Gail S Wright, Cristina Saura, Santiago Escrivá-de-Romaní,[...]. JAMA Oncol 2021
34
26


Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
8

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Sherene Loi, Anita Giobbie-Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jerusalem,[...]. Lancet Oncol 2019
159
8

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
Matthew C Franklin, Kendall D Carey, Felix F Vajdos, Daniel J Leahy, Abraham M de Vos, Mark X Sliwkowski. Cancer Cell 2004
739
8


DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa,[...]. Clin Cancer Res 2016
235
8

Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, Hope S Rugo, Stephen Jones, Seock-Ah Im, Karen Gelmon, Nadia Harbeck, Oleg N Lipatov, Janice M Walshe, Stacy Moulder,[...]. N Engl J Med 2016
8

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, M S Aapro, F André, C H Barrios, J Bergh, G S Bhattacharyya, L Biganzoli,[...]. Ann Oncol 2020
163
8

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Kimberly L Blackwell, Harold J Burstein, Anna Maria Storniolo, Hope Rugo, George Sledge, Maria Koehler, Catherine Ellis, Michelle Casey, Svetislava Vukelja, Joachim Bischoff,[...]. J Clin Oncol 2010
622
8

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
8

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Arlene Chan, Suzette Delaloge, Frankie A Holmes, Beverly Moy, Hiroji Iwata, Vernon J Harvey, Nicholas J Robert, Tajana Silovski, Erhan Gokmen, Gunter von Minckwitz,[...]. Lancet Oncol 2016
279
7

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
7

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
Gunter von Minckwitz, Andreas du Bois, Marcus Schmidt, Nicolai Maass, Tanja Cufer, Felix E de Jongh, Eduard Maartense, Christoph Zielinski, Manfred Kaufmann, Wolfgang Bauer,[...]. J Clin Oncol 2009
477
7

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
David Cameron, Michelle Casey, Michael Press, Deborah Lindquist, Tadeusz Pienkowski, C Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Gruszfeld, Bella Kaufman, John Crown,[...]. Breast Cancer Res Treat 2008
525
7

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Nancy U Lin, Virginia Borges, Carey Anders, Rashmi K Murthy, Elisavet Paplomata, Erika Hamilton, Sara Hurvitz, Sherene Loi, Alicia Okines, Vandana Abramson,[...]. J Clin Oncol 2020
101
7

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, I Bondarenko, S Paluch-Shimon, A Wardley, J-L Merot, Y du Toit,[...]. Ann Oncol 2019
35
20

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Nicholas Robert, Brian Leyland-Jones, Lina Asmar, Robert Belt, Des Ilegbodu, David Loesch, Robert Raju, Elizabeth Valentine, Robert Sayre, Melody Cobleigh,[...]. J Clin Oncol 2006
344
7

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
7

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Edith A Perez, Edward H Romond, Vera J Suman, Jong-Hyeon Jeong, George Sledge, Charles E Geyer, Silvana Martino, Priya Rastogi, Julie Gralow, Sandra M Swain,[...]. J Clin Oncol 2014
490
7

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Michel Marty, Francesco Cognetti, Dominique Maraninchi, Ray Snyder, Louis Mauriac, Michèle Tubiana-Hulin, Stephen Chan, David Grimes, Antonio Antón, Ana Lluch,[...]. J Clin Oncol 2005
6

Untangling the ErbB signalling network.
Y Yarden, M X Sliwkowski. Nat Rev Mol Cell Biol 2001
6

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Sara M Tolaney, Andrew M Wardley, Stefania Zambelli, John F Hilton, Tiffany A Troso-Sandoval, Francesco Ricci, Seock-Ah Im, Sung-Bae Kim, Stephen Rd Johnston, Arlene Chan,[...]. Lancet Oncol 2020
56
10

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Javier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, Teresa M Petrella, Karen Gelmon, Xavier Pivot, Shailendra Verma, Joan Albanell, Pierfranco Conte, Ana Lluch,[...]. J Clin Oncol 2012
166
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.